Vulvar cancer
Drug research and approvals for vulvar cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 59 studies of vulvar cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 59
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersNCT07902375 · Not applicable · Universiteit Antwerpen · starts Jun 19, 2026
- Evaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot StudyNCT07886203 · Not reported · Mayo Clinic · starts Oct 6, 2026
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast CancerNCT07741968 · Not applicable · City of Hope Medical Center · starts Sep 9, 2026
- Reirradiation and Total Ablative Strategies for Recurrent Gynecologic CancerNCT07667192 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Jun 11, 2026
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsNCT07454642 · Phase 1 · Avacta Life Sciences Ltd · starts Mar 31, 2026
- Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid TumorNCT07433283 · Phase 1 / Phase 2 · Sichuan Enray Pharmaceutical Sciences Company · starts Nov 12, 2024
- A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent…NCT07424664 · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jun 11, 2026
- Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal CancerNCT07407647 · Phase 2 · Ohio State University Comprehensive Cancer Center · starts Mar 12, 2026
Phase 2 8
- CarboplatinDNA inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- PaclitaxelTubulin inhibitor
- BleomycinDNA inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- LenvatinibVascular endothelial growth factor receptor inhibitor
- CadonilimabProgrammed cell death protein 1 inhibitor
- OmigananCell membrane disrupting agent
Phase 1 or earlier 5
- DocetaxelTubulin inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- NelfinavirHuman immunodeficiency virus type 1 protease inhibitor
- Edodekin alfa
- Pexipepimut-s
How its trials ended
189 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 30 whose ending is known, 33% met their primary endpoint, 7% missed it and 60% stopped early.
- Ongoing8042%
- Completed, result not reported6132%
- Status unknown1810%
- Met its primary endpoint105%
- Stopped: other or unclear105%
- Stopped: enrollment or feasibility74%
- Missed its primary endpoint21%
- Stopped: funding11%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Nov 29, 2022 | Groningen international study on sentinel nodes in vulvar cancer (groinss-v) iii: a prospective phase II treatment trialCarboplatin | Nrg Oncology | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA